All data are based on the daily closing price as of October 22, 2025
s
SanBio
4592.TSE
19.23 USD
0.72
+3.89%
Overview
Last close
19.23 usd
Market cap
1.39B usd
52 week high
25.59 usd
52 week low
2.68 usd
Target price
13.76 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
3458.1885
Price/Book Value
185.6111
Enterprise Value
1.57B usd
EV/Revenue
3405.5195
EV/EBITDA
-9.0194
Key financials
Revenue TTM
151605.04 usd
Gross Profit TTM
2.95M usd
EBITDA TTM
-25.21M usd
Earnings per Share
-0.33 usd
Dividend
N/A usd
Total assets
21.50M usd
Net debt
-9.23M usd
About
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson's disease, spinal cord injury, and Alzheimer's disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.